Lifyorli
Relacorilant · KIT · Corcept Therapeutics Incorporated
No Recall History
Plain English
Lifyorli is a kit containing relacorilant, taken oral. Manufactured by Corcept Therapeutics Incorporated.
Key Facts
- Brand Name
- Lifyorli
- Generic Name
- Relacorilant
- NDC Code (Product)
76346-450- Manufacturer
- Corcept Therapeutics Incorporated
- Dosage Form
- KIT
- Route
- ORAL
- Marketing Status
- Application #
- NDA220641
- Marketing Start
- 03/25/2026
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
abdominal discomfort1 reports
breath odour1 reports
eructation1 reports
hernia1 reports
nausea1 reports
nephrolithiasis1 reports
product odour abnormal1 reports
product use in unapproved indication1 reports
therapy interrupted1 reports
Frequently Asked Questions
What is Lifyorli used for?
Lifyorli contains Relacorilant. It is a kit taken oral. Consult your doctor for specific uses.
Is Lifyorli a controlled substance?
Lifyorli is not classified as a controlled substance by the DEA.
What is the generic name for Lifyorli?
The generic name for Lifyorli is Relacorilant. There are no other listed brand versions of Relacorilant.
What is the NDC code for Lifyorli ?
The NDC (National Drug Code) for Lifyorli is 76346-450, listed by Corcept Therapeutics Incorporated.
Other Lifyorli Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)